Analyst Price Target is $8.80
▲ +436.59% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Carisma Therapeutics in the last 3 months. The average price target is $8.80, with a high forecast of $12.00 and a low forecast of $6.00. The average price target represents a 436.59% upside from the last price of $1.64.
Current Consensus is
Buy
The current consensus among 5 polled investment analysts is to buy stock in Carisma Therapeutics. This Buy consensus rating has held steady for over two years.
Carisma Therapeutics, Inc., a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others. It is also developing in vivo CAR-M cell therapies in collaboration with Moderna Therapeutics to address multiple cancer targets; and multiple assets for the potential treatment of diseases beyond oncology, including fibrosis and other immunologic and inflammatory diseases. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.
Read More
